Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artículo |
| Language: | Inglés |
| Published: |
American Society for Microbiology
2024
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.12123/16603 https://journals.asm.org/doi/10.1128/msphere.00662-22 https://doi.org/10.1128/msphere.00662-22 |
| _version_ | 1855485789501128704 |
|---|---|
| author | Castro, Eliana Florencia Acosta, Julián Moriena, Lucía Rios Medrano, Mayra Cibello, Malena Tejerina Codino, Eduardo Taborda, Miguel Ángel Álvarez, Diego E. Cavatorta, Ana |
| author_browse | Acosta, Julián Castro, Eliana Florencia Cavatorta, Ana Cibello, Malena Tejerina Codino, Eduardo Moriena, Lucía Rios Medrano, Mayra Taborda, Miguel Ángel Álvarez, Diego E. |
| author_facet | Castro, Eliana Florencia Acosta, Julián Moriena, Lucía Rios Medrano, Mayra Cibello, Malena Tejerina Codino, Eduardo Taborda, Miguel Ángel Álvarez, Diego E. Cavatorta, Ana |
| author_sort | Castro, Eliana Florencia |
| collection | INTA Digital |
| description | SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection.
IMPORTANCE
Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels. |
| format | Artículo |
| id | INTA16603 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | American Society for Microbiology |
| publisherStr | American Society for Microbiology |
| record_format | dspace |
| spelling | INTA166032024-02-14T17:04:33Z Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination Castro, Eliana Florencia Acosta, Julián Moriena, Lucía Rios Medrano, Mayra Cibello, Malena Tejerina Codino, Eduardo Taborda, Miguel Ángel Álvarez, Diego E. Cavatorta, Ana Severe Acute Respiratory Syndrome Coronavirus 2 Humoral Immunity Immune Response Vaccination Coronavirus del Síndrome Respiratorio Agudo Grave 2 Inmunidad Humoral Respuesta Inmunológica Vacunación Argentina Sputnik V SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels. Instituto de Virología Fil: Castro, Eliana Florencia. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Castro, Eliana Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Castro, Eliana Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Acosta, Julián. Instituto de Biología Molecular y Celular de Rosario; Argentina Fil: Acosta, Julián. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Acosta, Julián. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina Fil: Moriena, Lucía. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública (CTSP); Argentina Fil: Rios Medrano, Mayra. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Rios Medrano, Mayra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin Fil: Cibello, Malena Tejerina. Universidad Nacional de San Martín. Escuela de Bio y Nanotecnologías; Argentina Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública; Argentina Fil: Taborda, Miguel Ángel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina Fil: Álvarez, Diego E. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Álvarez, Diego E. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Cavatorta, Ana. Instituto de Biología Molecular y Celular de Rosario; Argentina Fil: Cavatorta, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología En Salud Pública; Argentina 2024-02-14T16:56:51Z 2024-02-14T16:56:51Z 2023-06 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/16603 https://journals.asm.org/doi/10.1128/msphere.00662-22 2379-5042 https://doi.org/10.1128/msphere.00662-22 eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf American Society for Microbiology mSphere 8 (3) : e0066222 (June 2023) |
| spellingShingle | Severe Acute Respiratory Syndrome Coronavirus 2 Humoral Immunity Immune Response Vaccination Coronavirus del Síndrome Respiratorio Agudo Grave 2 Inmunidad Humoral Respuesta Inmunológica Vacunación Argentina Sputnik V Castro, Eliana Florencia Acosta, Julián Moriena, Lucía Rios Medrano, Mayra Cibello, Malena Tejerina Codino, Eduardo Taborda, Miguel Ángel Álvarez, Diego E. Cavatorta, Ana Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
| title | Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
| title_full | Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
| title_fullStr | Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
| title_full_unstemmed | Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
| title_short | Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
| title_sort | longitudinal follow up of the immunity to sars cov 2 in health care workers in argentina persistence of humoral response and neutralizing capacity after sputnik v vaccination |
| topic | Severe Acute Respiratory Syndrome Coronavirus 2 Humoral Immunity Immune Response Vaccination Coronavirus del Síndrome Respiratorio Agudo Grave 2 Inmunidad Humoral Respuesta Inmunológica Vacunación Argentina Sputnik V |
| url | http://hdl.handle.net/20.500.12123/16603 https://journals.asm.org/doi/10.1128/msphere.00662-22 https://doi.org/10.1128/msphere.00662-22 |
| work_keys_str_mv | AT castroelianaflorencia longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination AT acostajulian longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination AT morienalucia longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination AT riosmedranomayra longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination AT cibellomalenatejerina longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination AT codinoeduardo longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination AT tabordamiguelangel longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination AT alvarezdiegoe longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination AT cavatortaana longitudinalfollowupoftheimmunitytosarscov2inhealthcareworkersinargentinapersistenceofhumoralresponseandneutralizingcapacityaftersputnikvvaccination |